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Abstract
Background:  Mono-ADP-ribosyltransferase (ART) 1 belongs to a family of mammalian
ectoenzymes that catalyze the transfer of ADP-ribose from NAD+ to a target protein. ART1 is
predominantly expressed in skeletal and cardiac muscle. It ADP-ribosylates α7-integrin which
together with β1-integrin forms a dimer and binds to laminin, a protein of the extracellular matrix
involved in cell adhesion. This posttranslational modification leads to an increased laminin binding
affinity.
Results: Using C2C12 and C3H-10T 1/2 cells as models of myogenesis, we found that ART1
expression was restricted to myotube formation. We identified a fragment spanning the gene 1.3
kb upstream of the transcriptional start site as the functional promoter of the ART1 gene. This
region contains an E box and an A/T-rich element, two conserved binding sites for transcription
factors found in the promoters of most skeletal muscle specific genes. Mutating the DNA
consensus sequence of either the E box or the A/T-rich element resulted in a nearly complete loss
of ART1 promoter inducibility, indicating a cooperative role of the transcription factors binding to
those sites. Gel mobility shift analyses carried out with nuclear extracts from C2C12 and C3H-10T
1/2 cells revealed binding of myogenin to the E box and MEF-2 to the A/T-rich element, the binding
being restricted to C2C12 and C3H-10T 1/2 myotubes.
Conclusion: Here we describe the molecular mechanism underlying the regulation of the ART1
gene expression in skeletal muscle cells. The differentiation-dependent upregulation of ART1
mRNA is induced by the binding of myogenin to an E box and of MEF-2 to an A/T-rich element in
the proximal promoter region of the ART1 gene. Thus the transcriptional regulation involves
molecular mechanisms similar to those used to activate muscle-specific genes.
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Background
Mono ADP-ribosytransferases (ARTs) are an important
class of enzymes that catalyse the transfer of the ADP-
ribose from NAD+ to a specific amino acid residue in the
target protein [1,2]. This reaction has been originally iden-
tified as the pathogenic mechanism of bacterial toxins,
including cholera, pertussis and diphtheria toxin [3,4].
There is increasing evidence that endogenous ARTs also
play important roles in higher animals and human [5-7].
So far, the family of mammalian ARTs comprises five
members (ART1-5) [8]. They are all ectoenzymes,
anchored in the outer leaflet of the plasma membrane via
a glycosylphosphatidylinositol-tail with the exception of
ART5 which is secreted to the extracellular space [9].
Among the five ARTs, only ART1, ART2 and ART5 exhibit
enzyme activity whereas ART3 and ART4 appear to have
lost their catalytic activity [8,10]. ART1 was identified as
the first mammalian ART after protein purification from
skeletal muscle and cDNA cloning from rabbit [11],
human skeletal muscle [12] and mouse lymphoma cells
[13]. ARTs show a rather tissue-specific expression with
ART1 predominantly expressed in skeletal and cardiac
muscle [8,11,14]. ART3 and ART5 besides being abundant
in testis [8,14] are also expressed in muscle tissues.
In search of proteins being ADP-ribosylated by ART1 α7-
integrin was identified as a key protein [15,16]. α7-
integrin is expressed specifically in skeletal and cardiac
muscle, forms a dimer with β1-integrin, and binds to lam-
inin, an extracellular matrix protein [17,18]. ADP-ribo-
sylation has a positive effect on the interaction of α7/β1-
integrin with its ligand, laminin [19]. It may represent a
mechanism of upregulation of α7/β1-integrin function in
situations where enhanced interactions are required such
as muscle injuries or diseases [20].
Interestingly in mouse skeletal muscle cells, the expres-
sion of ART1 correlates with the transition from nondif-
ferentiated mononucleated myoblasts to multinucleated
nonreplicating myotubes [15]. This step is controlled by a
tightly regulated transcriptional program that involves
two key transcription factor families: the basic helix-loop-
helix protein (bHLH) family [21-24] consisting of MyoD,
Myf5, myogenin and MRF4 and the myocyte enhancer
binding factor 2 (MEF-2) family of the MADS-box factors
[25,26].
MEF-2 factors synergize with myogenic bHLH proteins to
regulate transcription and myogenesis. The DNA binding
recognition sequence of the bHLH proteins is an E box,
which is located in the regulatory regions of many muscle-
specific genes [27-29]. MEF-2 proteins bind as homo- and
heterodimers to an A/T-rich DNA consensus also found in
the promoter regions of nearly every known muscle-spe-
cific gene [30].
When analysing the promoter sequence from the ART1
gene we found putative myogenin and MEF-2 binding
sites, suggesting that these factors may participate in the
regulation of the ART1 gene. Using C2C12 and C3H-10T
1/2 cell lines, we show that activation of the ART1 pro-
moter is associated with differentiation of myoblasts into
myotubes. Mutation and deletion analysis of the pro-
moter revealed that myogenin and MEF-2 binding sites
are necessary and sufficient for transcriptional activity of
the promoter. Here we report for the first time that tran-
scription factors activating the promoter of most skeletal
muscle specific genes regulate transcription of ART1, an
enzyme involved in posttranslational modification of
adhesion proteins.
Methods
Material
Oligonucleotides were synthesized by Invitrogen GmbH
(Karlsruhe, Germany). Restriction enzymes (DpnI, XhoI,
BglII) and the exo-Klenow enzyme were obtained from
Fermentas GmbH (Saint Leon-Rot, Germany) and Pure
Yield™ Plasmid Mini Preparation System, pRL4.70 plas-
mid, pGL4.10 basic plasmid and the dual luciferase
reporter assay were purchased from Promega (Madison
MA, USA). The iQ™ SYBR® Green Supermix and the Brad-
ford assay were from Bio-Rad Laboratories GmbH
(München, Germany), poly(dIdCxdIdC) and etheno-
NAD+ were from Sigma (Taufkirchen, Germany).
Cell culture
The mouse C3H-10T 1/2 mesenchymal progenitor cell
line and stably MyoD transfected C3H-10T 1/2 cells, here
designated as MyoD-myoblasts, were obtained from Dr.
A. Buchberger (University of Braunschweig, Germany).
Cells were cultured in growth medium (37°C, 5% CO2)
consisting of Dulbecco's modified Eagle's medium
(DMEM), supplemented with 2 mM L-glutamine, 4.5 g/l
D-glucose, 100 U/ml penicillin, 100 μg/ml streptomycin
and 10% fetal bovine serum (FBS). The mouse C2C12 cell
line (a kind gift from Dr. Dr. T. Braun, Max-Planck-Insti-
tute for Heart and Lung Research, Bad Nauheim, Ger-
many) was cultured in the same growth medium
containing 20% instead of 10% FBS. Proliferating myob-
lasts (C3H10T 1/2-MyoD cells and C2C12 cells) were
grown at low density to prevent differentiation.
Fusion of myoblasts into myotubes was induced by grow-
ing cells to 80% confluence before replacing growth
medium by fresh medium supplemented with 2% horse
serum (HS) instead of FBS or by growing cell at conflu-
ence for several (5 up to 7) days in growth medium.
RNA isolation and reverse transcription
Total RNA was isolated from C3H-10T 1/2- and C2C12
cells (progenitors, MyoD-myoblasts, myoblasts, myo-BMC Molecular Biology 2008, 9:91 http://www.biomedcentral.com/1471-2199/9/91
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tubes) and from quadriceps skeletal muscles (CBA
mouse) using the RNeasy mini kit (Qiagen, Hilden, Ger-
many) according to the manufacturer's instruction. First-
strand cDNA was synthesized using 4 μg of total RNA in a
20 μl reverse transcripton reaction mixture as described
previously [31].
Polymerase chain reaction (PCR)
PCR reactions were performed as described previously
[10,32] with minor modifications. In brief, the following
primer pairs were used: mART1-full-UTR-fwd 5'-ATC CCA
GGA GAC CAG GTC AG-3' and mART1-full-rev 5'-GCA
CAG TTG ACC AGC CTT CT-3'; β2 m fwd: 5'-CTG ACC
GGC CTG TAT GCT AT-3' and β2 m rev: 5'-TTT TCC CGT
TCT TCA GCA TT-3'. Amplification of ART1- and beta-2
microglobulin (β2 m) mRNA was carried out at 61°C, 30
cycles and 60°C, 25 cycles respectively. The PCR products
were separated by electrophoresis on 1.8% agarose gels
(FMC Bioproducts, Rockland, MA, USA) containing 1.25
μg/ml ethidium bromide and visualized under ultraviolet
light. The 100 bp ladder (Invitrogen GmbH, Karlsruhe,
Germany) served as a standard.
Semi-quantitative real-time PCR
The reaction mixture contained 10 μl of the iQ™SYBR®
Green supermix, 125 nM forward and reverse primers and
1 μl of cDNA template in a final volume of 20 μl. The list
of intron-spanning primers amplifying ART1, ART3 and
ART5 cDNA is shown in Table 1. Samples were run in
duplicate in a 7300 real time PCR cycler system (Applied
Biosystems, Darmstadt, Germany). The reactions were
performed under the following conditions: initial dena-
turation at 95°C for 3 min, followed by 39 cycles of 15 s
denaturation at 95°C, 25 s of primer annealing 60°C
(except for ART5 – 61°C) and 28 s of extension/synthesis
at 72°C. Product quantification was optimal at 72°C,
except of ART1 (28 s at 83°C). Negative controls were per-
formed with total RNA or water as template. Following
PCR, the melting curve for each product was determined
and the correct size calculated by agarose gel analysis. All
cDNA products were confirmed by sequencing to check
their identity. Calculations were carried out as described
previously [33].
Treatment of cells with etheno-NAD+
C3H-10T 1/2 mesenchymal progenitors, MyoD-myob-
lasts and myotubes were harvested from 6 well cell culture
plates by incubating cells with PBS/EDTA at 4°C. After
washing cells were incubated in the presence or absence of
100 μM etheno-NAD+ for 30 min at 37°C, followed by
subsequent washing with PBS containing 10% Haemac-
cel® (Hoechst, Frankfurt, Germany) and 0.1% sodium
azide. Etheno-ADP-ribosylated proteins on the cell sur-
face were measured by FACS analysis as described previ-
ously [10]. The anti etheno-adenosine specific antibody
1G4 (IgG2a) [34] was kindly provided by Dr. F. Koch-
Nolte (University Medical Center Hamburg, Germany).
Luciferase reporter constructs
Genomic DNA was extracted from mouse C3H10T 1/2
cells. Two fragments of the ART1 promoter (pART1-L: -
1236/+37 and pART1-L: -322/+37 respective to the tran-
scription start site) were amplified by PCR using the
upstream primers (-1236) luc-pART1-L-fwd: 5'-TTT TTT
CTC GAG TTC TCT CGC ACC TCC CTT GT-3', (-322) luc-
mART1-S-fwd: 5'-TTT TTT CTC GAG CCA CCA CCA CCA
CAG AAC AA-3' (both tagged with a XhoI restriction site,
shown underlined) and (+37) luc mART1-rev2: 5'-TTT
TTT  AGA TCT ATG GCG GGC AAA GCT GAC CT-3'
(tagged with a BglII restriction site, shown in bold letters).
Both products were inserted in the promoter-, enhancer-
less pGL4.10 basic firefly  luciferase reporter plasmid
(Promega, Madison MA, USA). Recombinant plasmids
were isolated with the Pure Yield™ Plasmid Mini Prepara-
tion System (Promega, Madison MA, USA) and sequenced
to check their identity.
Table 1: List of intron-spanning primers used in real-time RT-PCR
target mRNA primer name oligonucleotides sequence (5' → 3' orientation)
mono ADP-ribosyltransferase 1 (ART1) ART1-rt_fwd
ART1-rt_rev
CAG GGG CTA CTC CTT TTT CC
CCC AGA CCT GCA CTT CTT TT
mono ADP-ribosyltransferase 3 (ART3) ART3-rt_fwd
ART3-rt_rev
AAT GGT CAC CAC GCT GCT
CCC TCT TCA TCT GCG GAA TA
mono ADP-ribosyltransferase 5 (ART5) ART5-rt_fwd
ART5-rt_rev
TGT GTC CTC AAG AGC AGT CG
CA ACT CTG GTT GGA CAG GT
hypoxanthine phosphoribosyltransferase 1 Hprt1_fwd
Hprt1_rev
CCA ACT TTG CTT TCC CTG GT
CTG GCC TGT ATC CAA CAC TTC
beta-2-microglobulin β2m_fwd
β2m_frev
CTG ACC GGC CTG TAT GCT AT
TTT TCC CGT TCT TCA GCA TTBMC Molecular Biology 2008, 9:91 http://www.biomedcentral.com/1471-2199/9/91
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Site-directed mutagenesis of the pGL4.10-pART1-S 
reporter construct
The pGL4.10-pART1-S construct was used as a template in
the QuickChange®  site-directed mutagenesis procedure
according to the manufacturer's instructions (Stratagene,
La Jolla, CA, USA). Forward and reverse primers used to
create the point mutations in the wild type E box and A/T
-rich element were: mART1-mut-E-box fwd: 5'-CAC ATT
TCT GAG tgG CTc TGT GGC GAC AGC AGG-3', mART1-
mut-E-box rev: 5'-CTG TCG CCA CAg AGC caC TCA GAA
ATG TGA CAC-3'; mART1-mut-A/T-rich fwd: 5' CAA GGA
GAC AGa gTG AAc acG ACG AGT GTC ACA TTT C-3' and
mART1-mut-A/T-rich rev: 5'-GTG ACA CTC GTC gtg TTC
Act CTG TCT CCT TGT CAA G-3'. Sequences shown in
bold lower case represent mismatch bases introduced to
obtain the desired mutation. Following amplification, the
reaction mixture was treated with DpnI to eliminate the
template DNA. Each of the mutated amplification prod-
ucts was transformed into the Escherichia coli DH 5α
strain. After having confirmed the desired mutations in
the mutated promoter sequence the mutated promoter
insert was subsequently cloned into a new pGL4.10 plas-
mid to ensure that no unwanted mutations occurred in
plasmid backbone.
Transient transfection and luciferase reporter gene assays
All transfections were carried out with FuGENE6®HD
(Roche, Mannheim, Germany) according to the manufac-
turer's instructions. For promoter reporter assays C3H10T
1/2-, C3H10T 1/2-MyoD- and C2C12 cells were seeded at
2 × 104 cells/0.5 ml growth medium in a 24-well cell cul-
ture plate. To induce differentiation of myoblasts into
myotubes, C3H10T 1/2-MyoD and C2C12 cells were
seeded at 2 × 105 cells/0.5 ml growth medium. Cells were
cotransfected with 400 ng pGL4.10 vector or 400 ng pro-
moter-reporter construct and 30 ng promoterless pGL4.70
(Promega, Madison MA, USA) per well, respectively. Each
transfection was carried out in triplicate. 20 h after trans-
fection the medium was replaced by fresh growth medium
or differentiation medium (to induce differentiation into
myotubes). Dual Luciferase Reporter Assays were carried
out 72 h after transfection in triplicate according to the
manufacturer's instructions. The firefly luciferase activity
was normalized to renilla luciferase activity in order to
compensate variations in transfection efficiencies. The
activity of the promoter-reporter constructs is given as fold
induction compared with the activity of the pGL4.10 pro-
moterless plasmid.
Electrophoretic mobility shift assay (EMSA)
DNA probes from the desmin gene E box, the N-10 gene A/
T-rich element and the ART1 gene E box and A/T-rich ele-
ment (wt/mut) were generated by annealing the forward
oligonucleotides listed in table 2 with the respective
reverse oligonucleotides. Fill-in labeling reactions were
carried out with [α-32P]dCTP (MP Biomedicals GmbH,
Eschwege, Germany) using the exo-Klenow enzyme.
C3H-10T 1/2 (Pg, MyoD-Mb, Mt) and C2C12 (Mb, Mt)
cells were washed with PBS, scraped into ice cold PBS and
centrifuged. Cell pellets were incubated 20 min at 4°C in
lysis buffer (10 mM Hepes-KOH, pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.5 μg/ml leu-
peptin, 0.5 μg/ml vanadat, 1 μg/ml pepstatin, 1 μg/ml
aprotinin and 1 μg/ml NaF) and subjected to vigorous
vortexing. Nuclei were collected and incubated with
extraction buffer (20 mM Hepes-KOH, pH 7.9, 10% glyc-
erol, 420 mM NaCl 1.5 mM MgCl2, 10 mM EDTA, 0.5 mM
dithiothreitol (DTT), 0.5 μg/ml leupeptin, 0.5 μg/ml
vanadat, 1 μg/ml pepstatin, 1 μg/ml aprotinin and 1 μg/
ml NaF) for 20 min at 4°C and subsequently sonicated for
a few seconds.
Clarified extracts were aliquoted and stored at -80°C. Ten
to fourteen micrograms of nuclear proteins were incu-
bated with binding buffer (10 mM Tris, pH 7.5, 40 mM
KCl, 0.5 mM DTT, 10% glycerol) for 25 min at room tem-
perature in the presence of 1 μg of poly(dIdCxdIdC)
(Sigma-Aldrich Inc.) and 1 μl [α-32P]-labelled DNA probe
(2 × 105 c.p.m.). To identify myogenin- or MEF2-contain-
ing complexes, 1 μg of mouse anti myogenin mAb (clone
FD5, Dako Cytomation) or 1 μg of anti MEF-2 polyclonal
antiserum (C-21, Santa Cruz Biotechnology) were added
to the assay mixture. As a negative control 1 μg mouse
IgG1 antibody (MOPC-21, Sigma-Aldrich Inc.) or rabbit
polyclonal IgG antiserum (C-16, Santa Cruz Biotechnol-
Table 2: List of forward oligonucleotides used for electrophoretic mobility shift assays (EMSA).
target name element wt/mut forward oligonucleotide sequences (5' → 3' orientation)
ART1 E box (-80/-54) wt: gg CAT TTC TGA GCA GCT GTG TGG CG ACA
mut: gg CAT TTC TGA GTG GCT CTG TGG CG ACA
A/T-rich (-169/-82) wt: gg AGG AGA CAG CTT GAA ATA GAC GAG TGT C
mut: gg AGG AGA CAG AGT GAA CAC GAC GAG TGT C
Desmin E box (-845/-820) wt: gg TTC GCC TTG GCA GCT GTT GCT CGT AG
N-10 A/T-rich wt: gg AGG AAA ACT ATT TAT AGA TCA AAT
Putative consensus sequences are indicated by bold letters. Positions of exchanged nucleotides in mutated (mut) DNA probes are in italic, bold 
letters. Lower case 'gg' denotes two added nucleotides used for fill-in labeling reactions.BMC Molecular Biology 2008, 9:91 http://www.biomedcentral.com/1471-2199/9/91
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ogy) were used. Protein-DNA complexes were electropho-
retically separated on 5% nondenaturing polyacrylamide
gels at 10°C using 0.5 × TBE (A/T-rich elements probes)
or 1 × TBE (E box probes) as running buffer. Gels were
dried and labelled complexes were visualized by a Phos-
phoimager system (Fuji).
Chromatin immunoprecipitation (ChIP) assays
ChIP-assays were carried out using C2C12 cells (Mt, Mb)
according to [35] with minor modifications: magnetic
Dynabeads® coupled with protein-G (Invitrogen GmbH,
Karlsruhe, Germany) were used instead of agarose beads
and the purification of DNA fragments was carried out
with the PCR-purification kit (Qiagen, Hilden, Germany)
instead of a chloroform/phenol extraction procedure.
Protein crosslinks were precipitated using 5 μg of a rabbit
polyclonal anti myogenin antiserum (M-225, Santa Cruz
Biotechnology), a rabbit polyclonal anti MEF-2 polyclo-
nal antiserum (C-21, Santa Cruz Biotechnology) or a rab-
bit polyclonal IgG antiserum (nr.-31450, Thermo
Scientific).
Samples were analysed by PCR as described previously
[10,32] using following primers: Chip-HPRT-1-fwd: 5'-
CTG CCT CTG CCT CCT AAA TG-3', Chip-HPRT-1-rev: 5'-
TGT CGT CTC CCA GAG GAT TC-3'; Chip-Desmin-
enhancer-fwd: 5'-TCA GCC TTC CTT GAC ACC TC-3',
Chip-Desmin-enhancer-rev: 5'-ACA CCA CGG GTT TGT
GTT TT-3'; Chip-mART1-fwd: 5'-GGG GTG ATC AGA GTC
CAG AA-3', Chip-mART1-rev: 5'-GGA GGG CAG CTT TCT
CTT TT-3'. Product amplification was carried out at 60°C
with 29 cycles using 1 μl precipitated DNA solution as
template.
Data analysis
Following programs were used: the standard nucleotide-
nucleotide BLAST [blastn] program [36] to screen genome
databases; Neural Network Promoter Prediction (NNPP),
available at BCM Search Launcher, to predict the ART1
promoter region and transcriptional start site; CLUSTAL
W software [37] for multiple amino acid sequence align-
ment, and the TESS program (Transcription Element
Search System) to predict transcription factor binding
sites and to browse the TRANSFAC database [38].
Results
Expression of ART1, ART3 and ART5 mRNA in myogenic 
cell lines during skeletal muscle differentiation in vitro
Among the five mammalian ARTs, ART1, ART3 and ART5
have been shown to be expressed in skeletal muscle [8].
Based on the finding that ART1 was absent from C2C12
mouse myoblasts but appeared with differentiation of
myoblasts to myotubes [15] it was of interest to determine
whether ART3 and ART5 followed a similar expression
pattern.
Real time RT PCR was carried out to measure ART1, 3 and
ART5 mRNA in the cell lines C3H-10T 1/2 and C2C12 at
various stages of differentiation. As seen in Fig. 1 all three
mRNAs are expressed in C2C12 and C3H-10T 1/2 myo-
tubes. They are neither detectable in the C3H-10T 1/2
mesenchymal progenitor cells nor, with the exception of
ART3 mRNA, in C2C12 and C3H-10T 1/2 myoblasts.
Thus ART5 similar to ART1 mRNA is strongly upregulated
during muscle cell differentiation. Upregulation of ART3
mRNA was only observed in C3H-10T 1/2 cells.
ADP-ribosylation of cell surface target proteins during 
muscle cell differentiation is restricted to the myotube 
stage
In previous studies Zolkiewska et al. [15] showed that
mono ADP-ribosylation of cell surface target proteins of
intact C2C12 cells was restricted to differentiated myo-
tubes. To test whether this also applied to C3H-10T 1/2
cells we incubated progenitor cells, MyoD-myoblasts and
myotubes with etheno-NAD+, an NAD+  analogue that
contains an ethenoadenosine moiety. The etheno-ADP-
ribosylated cell-surface proteins were visualized by flow
cytometry using an etheno-adenosine-specific mono-
clonal antibody (1G4). Fig. 2 shows that ADP-ribosylated
proteins are only present on differentiated C3H-10T 1/2
myotubes whereas they are neither found on progenitor
cells nor on the MyoD-myoblasts.
Among the three ARTs being expressed at the myotube
stage ADP-ribosylation of surface proteins can only be
attributed to ART1. ART3 lacks any detectable enzyme
activity [8,10] and ART5 can be excluded because it is
secreted instead of being cell attached [9].
To verify that ART3 in contrast to ART1 is enzymatically
inactive we analysed HEK 293-T cells stably transfected
with ART1 or ART3. Only on ART1-transfected cells ADP-
ribosylated proteins were detected (data not shown).
Structural and functional features of the putative ART1 
promoter
In contrast to the biological function of ART1 nothing is
known about the molecular mechanisms regulating ART1
gene expression in skeletal muscle cells. For this purpose
we cloned and analysed the promoter of the ART1 gene
(Fig. 3A).
To verify the structure and length of the 5'UTR of ART1
transcripts from C3H-10T 1/2- and C2C12 myotubes and
skeletal muscle tissue we performed RT-PCR analysis with
primers amplifying the full-length 5'untranslated region
(UTR) according to full-length data base ESTs entries [e.g.
GeneBank: BY709497, BY709074, BY703474,
CA460063.1] (data not shown). Respective to the tran-
scription start site (numbered with +1) a long (-1236/BMC Molecular Biology 2008, 9:91 http://www.biomedcentral.com/1471-2199/9/91
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+37) and a short (-322/+37) fragment of the putative
ART1  promoter region (Fig. 3B) were cloned into the
pGL4.10 basic firefly  luciferase reporter plasmid. After
transfection into C3H-10T 1/2 (Pg, MyoD-Mb, Mt) and
C2C12 (Mb, Mt) cells the promoter activities were deter-
mined using the dual luciferase reporter assays. The puta-
tive long- and the short ART1 promoter fragments only
showed basal promoter activity in C3H-10T 1/2 progeni-
Real-time RT-PCR analysis of ART1, ART3 and ART5 mRNA expression in myogenic cell lines during skeletal muscle differen- tiation in vitro Figure 1
Real-time RT-PCR analysis of ART1, ART3 and ART5 mRNA expression in myogenic cell lines during skeletal 
muscle differentiation in vitro. The mRNA of C3H-10T 1/2 and C2C12 cells at different stages of differentiation (progeni-
tors (Pg), MyoD-myoblasts (MoD-Mb), myoblasts (Mb), myotubes (Mt)) was isolated and mRNA levels of ART1, ART3 und 
ART5 were measured by semiquantitative real-time RT-PCR. Relative mRNA levels were standardized to the expression of 
beta-2 microglobulin housekeeping gene and mRNA concentrations from C3H-10T 1/2 cells (Mt) and C2C12 cells (Mt 6d, 
ART3 – Mt 3d) were set as the 100% reference. Asterisks indicate values less that 0.3%. Data are means ± S.D. of three inde-
pendent experiments. n.d.: not detectable.
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tor cells, C3H-10T 1/2 MyoD-myoblasts and C2C12
myoblasts. However, the activities of both fragments were
strongly upregulated after differentiation of the proliferat-
ing mononuclear myoblasts into non proliferating multi-
nuclear myotubes (Fig. 3B). Although compared with the
short fragment, the long fragment showed an increased
promoter activity, the major cis-regulatory elements
which mediate the myotube specific upregulation of the
promoter activity are located within the (-322/+37) frag-
ment.
To identify conserved putative binding sites for transcrip-
tion factors playing established roles in skeletal muscle
cell development, the genomic sequences of the ART1
proximal promoter from mouse, human and dog were
aligned using the CLUSTAL W software program [37] and
analysed using the Transcription Element Search System
(TESS) program [38]. Besides a classical TATA box motive,
analyses revealed the existence of two conserved cis-regu-
latory consensus sites, an E box motive (5'-CAGCTG-3')
and an A/T-rich element (5'-CTTGAAATAG-3') in the
ART1 proximal promoter regions (Fig. 4).
The E box and the A/T-rich element play a role in 
myotube-specific ART1 promoter activity
To gain insight into the functional importance of the pre-
dicted regulatory motifs in directing myotube-specific
promoter activity, the core consensus sequence of pre-
dicted sites was altered by mutagenesis of the parental
mouse proximal ART1  promoter construct pART1-S (-
322/+37). C3H-10T 1/2 (Pg, MyoD-Mb, Mt) and C2C12
(Mb, Mt) cells were transfected with the plasmids and pro-
moter activities were determined. As seen in Fig. 5 the
mutation of the (-64/-70) E box (5'-CAGCTG-3' to 5'-
TGGCTC-3') as well as the mutation of the (-90/-100) A/
T-rich element (5'-CTTGAAATAG-3' to 5'-AGTGAACACG-
3') results in a 90% decrease in the promoter inducibility
in myotubes compared with the parental wild-type con-
struct. Double mutant shows residual promoter activity
while the differentiation-specific induction is completely
lost, indicating that indeed both motifs are of functional
importance for myotube restricted ART1 promoter activa-
tion. As both motives are in close vicinity a cooperative
role of the transcription factors binding to those motifs
might be expected.
Etheno-ADP-ribosylation of cell-surface proteins on C3H-10T1/2 cells Figure 2
Etheno-ADP-ribosylation of cell-surface proteins on C3H-10T1/2 cells. C3H-10T 1/2 cells at different stages of differ-
entiation (progenitors, MyoD-myoblasts, myotubes) were incubated for 30 minutes in the absence (dashed lines) or presence 
(solid lines) of 100 μM etheno-NAD. Cells were then washed, incubated with the primary monoclonal antibody 1G4, stained 
with a FITC-conjugated goat-anti-mouse secondary antibody and subjected to FACS analysis. Data show one representative 
experiments out of three.
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The activity of a short and a long ART1 promoter fragment is upregulated during myotube formation Figure 3
The activity of a short and a long ART1 promoter fragment is upregulated during myotube formation. (A) 
Shown is the exon-intron structure of the mouse ART1 gene as described previously [58]. Exons 1–5 are represented by 
boxes, introns by thin lines. Coding regions are indicated in black, non-coding regions in white. (B) A long (-1236/+36) and a 
short (-322/+37) fragment of the putative mouse ART1 promoter region (pART1-L: grey bars and pART1-S: black bars, respec-
tively) was cloned into the pGL4.10 firefly luciferase reporter plasmid. C3H-10T 1/2 (Pg, MyoD-Mb, Mt) and C2C12 (Mb, Mt) 
cells were transfected with the plasmids and promoter activities were determined using the dual luciferase reporter assays 
normalized to renilla luciferase activity. Promoter activities are shown as fold activation respective to the pGL4.10 basal activity 
(pGL4.10 = 1). The data represent means ± S.D. of three independent experiments in triplicate. An arrow indicates the tran-
scription start site numbered with +1 and 'luc' boxed indicates the firefly luciferase gene.
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Binding of myogenin to the proximal E box during muscle 
cell differentiation
Given the crucial role of the E box and the A/T-rich ele-
ment in myogenic differentiation, we asked whether the
functional properties of these sites are reflected by distinct
DNA-protein interactions. Extensive analyses of skeletal
muscle differentiation have shown that myogenic regula-
tory factors (MRFs) of the basic helix-loop-helix proteins
(bHLH) family [21-24] are involved in skeletal muscle
development. These bHLH factors (e.g. MyoD, Myf5,
Two conserved cis-regulatory consensus sites in the ART1 proximal promoter regions of mouse, human and dog are putative  candidates for muscle specific gene expression Figure 4
Two conserved cis-regulatory consensus sites in the ART1 proximal promoter regions of mouse, human and 
dog are putative candidates for muscle specific gene expression. Genomic sequences of the ART1 proximal promoter 
from human (NT_039433.7), mouse (NT_009237.17) and dog (AAEX02028845.1) were aligned using the CLUSTAL W soft-
ware program [37] and analysed using the Transcription Element Search System (TESS) program [38]. The transcription start 
site (TSS) numbered with +1 is indicated by an arrow. The numbering of the nucleotides refers to the nucleotide position rel-
ative to the putative TSS. Conserved putative cis-elements are indicated by black boxes with sequences in white. A TATA box 
is shown in bold underlined lower case. The nucleotide sequence of exon 1 is shown in bold upper case, promoter and intron 
border in lower case. The symbol '-' indicates the lack of a corresponding sequence and '*' the identity between nucleic acids.
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An A/T-rich motif and an E box mediate the induction of the ART1 proximal promoter activity during myogenesis Figure 5
An A/T-rich motif and an E box mediate the induction of the ART1 proximal promoter activity during myogen-
esis. Candidate motifs for mediating muscle-specific expression of the mouse proximal ART1 promoter were altered by site-
directed mutagenesis of the pART1-S (-322/+37) containing pGL4.10 plasmid. Cells at different stages of differentiation were 
transfected with the plasmids. Promoter activities were determined using the dual luciferase reporter assays normalized to 
renilla luciferase activity. Following symbols are used: black box – A/T-rich element (A/T); black oval – E box (E); white box – 
TATA box (TB) and 'luc' boxed – firefly luciferase gene. An arrow indicates the transcription start site numbered with +1. Muta-
tions of symbolised A/T-rich element (A/T) and E box (E) are indicated by an X overlay. The data represent means ± S.D. of 
three independent experiments in triplicate.
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MRF-4, myogenin) bind as homo- or heterodimers with
ubiquitously expressed E-proteins to a specific E box
motive [39] in prominent muscle specific promoters and
enhancers. Genetic studies indicate that MyoD and Myf5
are necessary to specify the skeletal muscle lineage [40]
whereas myogenin appears to have a critical role in termi-
nal differentiation of the specified muscle cells in vivo
[41,42]. Because ART1 expression and the activity of the
two cloned ART1 promoter fragments are restricted to dif-
ferentiated non-proliferating multinuclear myotubes,
myogenin was considered a favourite candidate to bind to
the E box in the proximal ART1 promoter as a cis-regula-
tory factor. To test this hypothesis electrophoretic mobil-
ity shift assays (EMSA) were performed using the (-64/-
70) E box from the ART1 proximal promoter as an EMSA
probe (Fig. 6). As a positive control a probe containing a
myogenin binding E box of the desmin gene promoter [43]
was used.
As seen in Fig. 6 incubating nuclear extracts of C3H-10T 1/
2- and C2C12 myotubes with the E box oligomer probe
lead to the formation of a shifted complex that was not
detectable in the presence of a mutated E box probe. The
E box specific complex was supershifted by an anti-myo-
genin antibody but not by the corresponding isotype con-
trol confirming the specificity of the supershift. No
supershift was observed when the experiments were car-
ried out with nuclear extracts of myoblasts.
Binding of MEF-2 to the A/T-rich element during muscle 
cell differentiation
Since the A/T-rich element in the ART1  proximal pro-
moter is crucial for its activation as demonstrated by the
luciferase reporter assay, we aimed to identify transcrip-
tion factors that may bind to this site. According to the
TESS program (Transcription Element Search System)
myocyte enhancing factor 2 proteins (MEF-2), especially
Myogenin from myotube nuclear proteins extracts binds to the wild-type ART1 promoter E box Figure 6
Myogenin from myotube nuclear proteins extracts binds to the wild-type ART1 promoter E box. Gelshift assays 
were performed by incubation of the [α-32P]dCTP labelled probe containing the E box (WT) of the ART1 gene promoter with 
nuclear protein extracts (NE) of C3H-10T 1/2 (MyoD-Mb, Mt) and C2C12 (Mb, Mt) cells. The specificity of the protein binding 
at the E box site was assessed by the use of a labelled probe containing a mutated ART1 E box sequence (Mut). For supershift 
assays, reaction mixtures were preincubated with antibodies (Ab) against myogenin (αMG) or with a non-specific isotype (ISO) 
as a negative control. Specific retarded protein/probe complexes are marked by white arrows and supershifted complexes by 
black arrows. As a positive control a probe containing a myogenin binding E box of the desmin gene promoter [43] was used.
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MEF-2A, are predicted to be candidates. MEF-2 binds to
5'-YTA(T/A)4TAR-3' [44] sequences in the regulatory
regions of target genes. Although the sequence of the (-90/
-100) ART1 A/T-rich element (5'-CTTGAAATAG-3') does
not completely match the optimal consensus sequence it
may bind MEF-2 protein.
To demonstrate binding of MEF-2 proteins to the A/T-rich
site we performed gel-shift experiments using synthetic
DNA probes of this element and nuclear extracts from
C3H-10T 1/2- and C2C12 myotubes. As a positive control
a probe containing a MEF-2 binding site of the N-10 gene
promoter [25,45] was used. As shown in Fig. 7 nuclear
extracts from C3H-10T 1/2- and C2C12 myotubes inter-
acted with the oligomer probes whereas no specific com-
plexes were formed when extracts from myoblasts or
mutated oligonucleotide probes of the A/T-rich elements
were used. Addition of an anti-MEF-2 antibody resulted in
a supershift indicating that MEF-2 in fact interacts with the
A/T-rich promoter region.
Binding of myogenin and MEF-2 to the ART1 promoter 
during muscle cell differentiation in vivo
To confirm that endogenous nuclear myogenin and MEF-
2 bind to the proximal part of the ART1 promoter in vivo,
chromatin immunoprecipitation (ChIP) assays were car-
ried out with C2C12 myotubes and myoblasts. As seen in
Fig. 8, both myogenin and MEF-2 bind to the ART1 pro-
moter in myotubes, but not in myoblasts.
MEF-2 from myotube nuclear protein extracts binds to the wild-type ART1 promoter A/T-rich element Figure 7
MEF-2 from myotube nuclear protein extracts binds to the wild-type ART1 promoter A/T-rich element. Gelshift 
assays were performed by incubation of the [α-32P]dCTP labelled probe containing the A/T -rich element (WT) of the ART1 
gene promoter with nuclear protein extracts (NE) of C3H-10T 1/2 (MyoD-Mb, Mt) and C2C12 (Mb, Mt) cells. The specificity 
of the protein binding at the A/T-rich element was assessed by the use of a labelled probe containing a mutated ART1 A/T-rich 
sequence (Mut). For supershift assays, reaction mixtures were preincubated with antibodies (Ab) against MEF-2 (αMEF-2) or a 
non-specific isotype (ISO) as a negative control. Specific retarded protein/probe complexes are marked by white arrows and 
supershifted complexes by black arrows. As a positive control a probe containing an MEF-2 binding box of the N-10 gene pro-
moter [25] was used.
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As a positive control the desmin gene promoter enhancer
[43] that contains a functional E box and functional MEF-
2 binding site and as a negative control the proximal part
of the HPRT-1 housekeeping gene promoter were used.
Whereas both factors bind to the desmin gene promoter
enhancer in a myotube restricted manner, no binding to
the HPRT-1 gene promoter was observed.
Discussion
The discovery of eukaryotic mono-ADP-ribosyltrans-
ferases (ARTs) is fairly recent [46,47]. Although the chro-
mosomal localization, genomic organization and
expression of the five mammalian ART  genes are well
understood nothing is known about the transcriptional
control of these genes. The fact that three of the five mam-
Myogenin and MEF-2 bind to the ART1 promoter in myotubes, but not in myoblasts in vivo Figure 8
Myogenin and MEF-2 bind to the ART1 promoter in myotubes, but not in myoblasts in vivo. The chromatin from 
C2C12 cells (myoblasts and differentiated myotubes) was cross-linked with formalin. Cells were lysed, the nuclear extracts 
were prepared and sonicated (four times 15 strokes; output, 70%; duty cycle, 60%; Bandelin Sonopuls GM70, Bandelin, Berlin, 
Germany). After precipitation with antibodies against myogenin (αMG), MEF-2 (αMEF-2) or with an unspecific IgG isotype anti-
body (Iso) as a control, the ART1 promoter region containing the E box und the A/T rich element was amplified by PCR from 
the precipitated DNA. Lanes are input DNA (Input) in dilutions: (1/100) 1:100, (1/10) 1:10 und undiluted (1), no antibody (no), 
water control (H2O) and DNA ladder (M). The PCR amplification of the desmin gene promoter enhancer [43] which contains 
a functional E box and a functional MEF-2 binding site served as a positive control whereas the amplification of the proximately 
part of the HPRT-1 housekeeping gene promoter served as negative control.
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malian ARTs namely ART1, ART3 and ART5 are highly
expressed in skeletal muscle tissue made us analyse their
transcriptional regulation during muscle cell differentia-
tion in more detail. We used C2C12 and C3H-10T 1/2
cells, which provide well-established and reproducible
models of myogenesis [48,49]. We found that ART1 and
ART5 expression was restricted to myotubes while ART3
mRNA was already present in myoblasts of both cell types
but absent from C3H-10T 1/2 mesenchymal progenitor
cells. In previous studies we showed that the ART3 pro-
moter consists of three regions (pα, pβ and pγ) and that
the pβ promoter is preferentially used in skeletal muscle
[10]. In line with these findings we observed an almost
exclusive usage of the pβ promoter in C3H-10T 1/2 myob-
lasts transfected with the transcription factor MyoD (data
not shown) suggesting that the promoter is a direct or
indirect target of MyoD.
When defining the 5'bounderies of the ART5 gene and
comparing them to the 5'flanking sequences of the ART1
gene Glowacki et al. [14] found that the two genes overlap
at their 5'ends. Since both genes are coexpressed in heart-
and skeletal muscle and as shown here in non-proliferat-
ing multinuclear myotubes and since the muscle-specific
transcription start site of the ART5 gene overlaps with the
5'end of the ART1 gene one could speculate that their
expression is regulated by a common promoter or regula-
tory element. Interestingly in testis, which contains ART5
but not ART1 mRNA, the transcription start site of ART5
lies outside the ART1 gene [14].
To understand the myotube specific expression of the
ART1 gene in more detail we cloned and analysed the
ART1 promoter. We identified a fragment spanning the
nucleotide sequence from position -322 to +37 respective
to the transcription start site (+1) as a functional pro-
moter. We identified an E box and an AT-rich element in
the promoter region, two binding sites for transcription
factors with established roles in skeletal muscle develop-
ment. By distinct DNA-protein interaction we showed
binding of the transcription factors myogenin to the E box
and MEF-2 to the A/T-rich element in vitro. We confirmed
the binding of these factors to the proximal part of the
ART1 promoter in vivo.
Extending the fragment to -1236 resulted in an increase in
promoter activity suggesting the existence of additional
enhancer elements within the -3221/-1236 region.
Indeed, by using bioinformatics tools we have identified
four additional cis-regulatory consensus sites: an A/T-rich
motif (-1208,-1198) and three E boxes ((-1096,-1088), (-
841,-836) and (-755,-750)), which were only present in
the long fragment of the mouse ART1 promoter [see Addi-
tional file 1]. These putative binding sites for MEF-2 and
bHLH-factors are potential candidates for enhancing mus-
cle specific gene expression. Such enhancer elements are
frequently found in the promoter region of prominent
muscle specific genes (such as the desmin-[50,51] and the
muscle creatin kinase gene [52]).
In addition to myogenin the other members of the muscle
regulatory factors (MRFs) family, Myf5, Mrf-4 and MyoD
are also expressed in skeletal muscle and play distinct but
overlapping roles in regulating muscle cell development
[53]. MyoD for example when introduced into C3H-10T
1/2 mesenchymal progenitor cells is able to convert the
cells into myoblasts and as shown here to increase ART3
mRNA expression. For ART1 to become expressed it
requires differentiation of myoblasts to myotubes. This
process, which is achieved by removing serum from the
cell cultures or by increasing cell-cell contact results in the
activation of MyoD dependent transcription factors like
myogenin (cross activation) the latter being essential for
ART1 activation. Together with myogenin, MEF-2 proteins
function combinatorially to activate ART1 transcription.
These data show that ART1 expression is regulated in a
similar way as the majority of skeletal muscle genes,
which also require the coordinated activity of members of
the two families of transcriptional regulators, MRF and
MEF-2.
The myocyte enhancer factor 2 (MEF-2) belongs to the
MADS (MCM1, agamous, deficiens, serum response fac-
tor) family of transcriptions factors. MEF-2 homo- or het-
erodimers bind an A/T-rich DNA sequence (5'-YTA(T/
A)4TAR-3') [44] within the regulatory regions of several
muscle specific genes [30].
Although the A/T rich DNA sequence within the ART1
promoter (5'-CTTGAAATAG-3') does not reflect a perfect
match with the MEF-2 consensus sequence, MEF-2 binds
to the sequence in the ART1 promoter. It contains the
nucleotides TG at position 3 and 4 instead of an AA or AT,
an unusual nucleotide sequence for a MEF-2 binding site.
In case of a perfect MEF-2 consensus sequence in the ART1
promoter a sequence (5'-C TAT(A)AAA  TAG-3') would
result that contains a TATA box. A TATA box within the
MEF-2 binding site in the ART1 promoter would only be -
64 nucleotides upstream of the classical TATA box (-30/-
25) of the promoter. If this putative sequence was used, a
premature transcription start or interference with binding
of MEF-2 could result. In either case a successful expres-
sion of ART1 would be questionable.
MEF-2 and myogenic bHLH factors play key roles in skel-
etal muscle development [40-42,54]. Both factors physi-
cally interact as part of a combinatorial complex that
results in synergistic activation of transcription and myo-
genesis [54,55]. Cooperative activation is facilitated by
the close proximity and coordinated positioning of theBMC Molecular Biology 2008, 9:91 http://www.biomedcentral.com/1471-2199/9/91
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binding sites of MyoD and MEF-2 on the same face of the
DNA in most muscle-specific promoters [56]. Wright et al.
(1991) [27] found that MEF-2 binding sites are frequently
associated with functional E boxes bound by myogenin
and that these sites are often positioned with precise spac-
ing to allow both factors to bind DNA simultaneously,
which likely promotes protein-protein interactions by
these factors [56]. Here we show that the binding sites for
myogenin and MEF-2 in the ART1  promoter are also
located in close vicinity separated by a short spacer of 19
nucleotides, sufficient to allow both factors to bind to
DNA simultaneously. Furthermore the finding that
mutating either the E box or the A/T-rich element results
in a 90% decrease in the promoter inducibility during dif-
ferentiation and that a double mutant construct hardly
shows any promoter inducibility implies a cooperative
role of the two transcription factors in regulating ART1
transcription during myogenesis.
To exert its effects i.e. to ADP-ribosylated α7 integrin the
ART1 protein requires NAD+. Under physiological condi-
tions the concentration of free NAD+ in the extracellular
compartment is in the submicromolar range [57] too low
to attain significant activities. An increase could occur as a
consequence of cell lysis during an infection or tissue
injury or due to membrane injuries as a result of meta-
bolic and mechanical stress (reviewed in [20]). Once acti-
vated, ART1 ADP-ribosylates α7-integrin, which together
with β1-integrin binds to laminin. As ADP-ribosylation
leads to an increased ligand binding, it may represent a
mechanism of upregulation of α7β1-integrin function in
vivo in injured or diseased muscle upon loss of plasma
membrane integrity and efflux of NAD+ [20].
The data presented here demonstrate that expression of
the  ART1  gene during myogenesis is under control of
myogenin and MEF-2, two transcription factors critical for
the activation of many skeletal muscle specific genes. Hav-
ing identified the ART1 promoter it will be of interest if
genetic defects and polymorphisms in the ART1 gene are
associated with degenerative muscle diseases.
Conclusion
The ectoenzyme ART1 is predominantly expressed in skel-
etal and cardiac muscle. It ADP-ribosylates α7-integrin, a
cell surface protein of myotubes, which has a positive
effect on the interaction of the α7β1 dimer with its ligand
laminin [19]. Using C2C12 and C3H-10T 1/2 cells as a
model of myogenesis we found that activation of the
ART1 gene was restricted to the myotube stage. We identi-
fied the ART1 promoter and showed that it is regulated by
the two transcription factors MEF-2 and myogenin, which
play an essential role during muscle cell differentiation in
the regulation of muscle-specific genes. An understanding
of the transcriptional regulation of the ART1 gene should
facilitate a better understanding of the regulation of ART1
expression under physiological and pathological condi-
tions.
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